RxDoctor Payments Data

Vijaya Challa, MD

Internal Medicine · Allen Park, MINPI 1528016490

Payments from drug & device makers

$1,263in general payments, 2019–2025

Across 72 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$304
  • GSK$219
  • Exact Sciences$180
  • Pfizer$178
  • Novartis$92
  • E.r. Squibb & Sons, L.L.C.$54
  • plus $236 from 10 others

What the payments were for

  • Food & beverage$1,263100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,263 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$91,540
Medicare patients
173
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$98,436
JanuviaSitagliptin Phosphate59$51,208
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$51,078
EntrestoSacubitril/Valsartan15$22,449
JardianceEmpagliflozin20$22,435
FarxigaDapagliflozin Propanediol26$17,433
XareltoRivaroxaban13$14,707
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl73$9,843
Breo ElliptaFluticasone/Vilanterol16$9,125
Insulin Lispro Kwikpen U-100Insulin Lispro22$8,130
Spiriva HandihalerTiotropium Bromide12$7,079
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,789
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,018
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen442$5,447
Albuterol Sulfate HfaAlbuterol Sulfate112$4,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$178$98,43688 claims
GSKTrelegy Ellipta, Breo Ellipta$219$60,20361 claims
MerckJanuvia$39$51,20859 claims
NovartisEntresto$92$22,44915 claims
AstraZenecaFarxiga$304$17,43326 claims
Sanofi-aventis U.S. LLCLantus$36$3,92617 claims
Orexo US, Inc.Zubsolv$21$1,82312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Allen Park

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →